Homocysteine-lowering interventions for preventing cardiovascular events
John Wiley & Sons, Ltd, January 2015
Martí-Carvajal, Arturo J, Solà, Ivan, Lathyris, Dimitrios
Cardiovascular disease, which includes coronary artery disease, stroke and congestive heart failure, is a leading cause of death worldwide. Homocysteine is an amino acid with biological functions in methionine metabolism. A postulated risk factor is an elevated circulating total homocysteine level, which is associated with cardiovascular events. The impact of homocysteine-lowering interventions, given to patients in the form of vitamins B6, B9 or B12 supplements, on cardiovascular events. This is an update of a review previously published in 2009 and 2013.
The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.
|Members of the public||12||80%|
|Practitioners (doctors, other healthcare professionals)||2||13%|
The data shown below were compiled from readership statistics for 230 Mendeley readers of this research output. Click here to see the associated Mendeley record.
|Readers by professional status||Count||As %|
|Student > Master||44||19%|
|Student > Ph. D. Student||26||11%|
|Student > Bachelor||26||11%|
|Student > Postgraduate||20||9%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||99||43%|
|Nursing and Health Professions||23||10%|
|Agricultural and Biological Sciences||19||8%|
|Biochemistry, Genetics and Molecular Biology||9||4%|
|Pharmacology, Toxicology and Pharmaceutical Science||7||3%|